Result of AGM

Medpal AI PLC

30 March 2026

 

30 March 2026

MedPal AI plc

("MedPal AI" or the "Company")

Result of AGM

MedPal AI plc (AIM:MPAL, FRA Z1N), the digital health and AI company, announces that, at the annual general meeting of the Company held today, all of the resolutions were passed. The results of the poll vote are set out below.

Summary of Resolutions	For	Percentage of votes in Favour	Against	Percentage of votes Against	Withheld	Total of issued share capital voted	Percentage of issued share capital voted
1 Receive the consolidated annual report and accounts for the year ended 31 August 2025	224,919,529	99.98%	38,956	0.02%	116,470	224,958,485	45.68%
2 Reappoint Jason Drummond as a director of the Company	224,809,794	99.95%	122,314	0.05%	142,847	224,932,108	45.68%
3 Reappoint Kevin O'Neill as a director of the Company	224,811,214	99.95%	120,894	0.05%	142,847	224,932,108	45.68%
4 Reappoint Justin Drummond as a director of the Company	224,869,171	99.97%	65,279	0.03%	140,505	224,934,450	45.68%
5 Reappoint Adam Monaco as a director of the Company	224,810,542	99.95%	121,391	0.05%	143,022	224,931,933	45.68%
6 Reappoint Grant Thornton Limited as auditors	224,805,257	99.96%	100,743	0.04%	168,955	224,906,000	45.67%
7 To authorise the Directors to determine the fees payable to the auditors	224,632,019	99.92%	190,457	0.08%	252,479	224,822,476	45.65%
8 To authorise the Directors to allot ordinary shares and relevant securities pursuant to Section 551 of the Companies Act 2006.	224,514,082	99.80%	445,098	0.20%	115,775	224,959,180	45.68%
9 To disapply pre-emption rights in certain circumstances (general authority).	224,643,956	99.88%	271,975	0.12%	159,024	224,915,931	45.67%

Notes:

A vote "withheld" is not a vote in law and has not been counted as a vote "for" or "against" a resolution.

Resolutions 1 to 8 were passed as Ordinary Resolutions. Resolution 9 was passed as a Special Resolution

The number of ordinary shares in issue at the date of this announcement is 492,441,036, of which no ordinary shares are held in treasury.

Enquiries:

MedPal AI plc Jason Drummond, Chief Executive Officer	Via Square1 Consulting
Cairn Financial Advisers LLP        Louise O'Driscoll/Jo Turner	[phone]
Clear Capital Markets Limited Bob Roberts	[phone]
Square1 Consulting David Bick	[phone] [phone]

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.

 

END